This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. The aim of the project is to establish a clinical platform to collect representative data on molecular testing, sequence of systemic tumor therapy and other therapies, and disease progression of patients with lung cancer. A special focus will be on molecular biomarker testing and reflex NGS testing. Another aim of the registry is the collection of quality indicators in lung cancer care. The results of the register will be used to describe the current state of care and to develop it further for the future.
Informed consent
Histologically confirmed lung cancer
Age ≥ 18 years
Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments
None
All unselected patients diagnosed with lung cancer at the research sites. The study is intended to commence at two sites in Vienna, with subsequent invitation of participation of other sites.
Ecologic or community
Prospective
Not listed
NGS Testing
To assess molecular biomarker testing and indicators of the quality of care in patients with lung cancer
Click on the lead sponsor to view all of their trials.
